Navigation Links
Agendia Opens CLIA-Registered U.S. Genomics Laboratory

HUNTINGTON BEACH, California and AMSTERDAM, May 26 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the opening of its U.S. clinical genomics laboratory in Huntington Beach, CA. The laboratory is fully-licensed and compliant with the Clinical Laboratory Improvements Amendments (CLIA) as administered by the Centers for Medicare and Medicaid Services (CMS).

In addition to opening its U.S. cancer genomics laboratory, Agendia has over the past months made several key additions to its domestic-based senior executive team. The team consists of Dr. Richard Bender, Chief Medical Officer, Mr. Daniel Forche, Vice President of Sales & Marketing, Mr. Alan B. Carter, Vice President of Global Business Development, and pathologist Dr. Chynel Henning, Laboratory Director.

"Our new genomics lab's capacity will allow us to meet the increasing demand for MammaPrint across the United States and give physicians and patients optimal test result turnaround and unmatched service and support," noted Jan Groen, Ph.D., Chief Operating Officer. "This expansion places us in an excellent position to continue making advancements in molecular cancer diagnostics and equip oncologists with powerful tools to use in the fight against breast cancer."

Dr. Bernhard Sixt, President and Chief Executive Officer, added, "the opening of the Huntington Beach laboratory and the appointment of our U.S.-based commercial team provide a strong basis for our U.S. operations and for Agendia's next phase of growth. Our enhanced domestic capabilities will help us to further drive adoption of MammaPrint, and place us in an even better position to collaborate with a growing number of clinical, academic, and industrial partners here in the U.S."

Dr. Bender has more than 30 years of medical and professional experience as a practicing oncologist and director of several oncology programs. Dr. Bender has served as Medical Director of the Hematology/Oncology Program at Quest Diagnostics, Director of Medical Oncology and Hematology at Kaiser Permanente Medical Group, Director of Strategic Development in Medical Oncology/Hematology at Johnson & Johnson, and as an investigator at the National Cancer Institute and Scripps Clinic and Research Foundation. Currently, Dr. Bender serves as an expert reviewer in oncology for the Medical Board of California, co-Editor of Anti-Cancer Drugs, an international journal on anti-cancer agents, and as a clinical instructor in medicine at the University of California, Irvine School of Medicine.

Mr. Forche brings more than 18 years of sales, marketing and commercial leadership experience in the diagnostics arena. Prior to joining Agendia, Mr. Forche was the Senior Vice President of Sales and Marketing for Insight Health Corporation, a national leader in diagnostic imaging services. He also served as Vice President of Marketing at US LABS, an industry leader in cancer diagnostic and genomic testing services, and has held sales and marketing management roles at Ventana Medical Systems (now Roche) and Abbott Laboratories.

Mr. Carter joins Agendia with 25 years of global business development experience from a number of top-tier life sciences companies such as BioTrove, Celera, Applied Biosystems, and Perkin Elmer. At Agendia, he oversees ongoing strategic alliances within the bio-pharmaceutical sector and collaboration with partners interested in Agendia's expanding molecular diagnostics portfolio.

Chynel Henning, M.D., Ph.D., FASCP, FCAP, joins Agendia with more than 30 years of experience as a laboratory director. He is currently also Director of National Cyto-Path Laboratories and Professional Pathology Medical Group Laboratory, both in Long Beach, California; and Director of the Laboratory and Department of Pathology at the Miracle Mile Medical Center, Los Angeles. Dr. Henning is a Fellow of the American Society of Clinical Pathologists and the College of American Pathologists.

Ongoing research and development commitments continue to augment Agendia's ability to accurately predict breast cancer recurrence and sub-typing, and help physicians tailor individual treatment plans to their patients. Agendia's goal is to provide women with answers to crucial treatment questions, such as how their breast cancer will respond to targeted therapies or various chemotherapy regimens.

For more information, please visit

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatment within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer therapy. The company markets four products, with several new genomic tests in development. Agendia collaborates with pharmaceutical companies in the development of highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit

SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
2. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
3. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
4. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
5. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
6. Agendia Appoints VP of Business Development
7. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
8. Agendia Appoints New Chief Financial Officer
9. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
10. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
11. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
Post Your Comments:
(Date:10/8/2015)... and WAYNE, Pa. , ... and technology consulting firm, has announced the call for ... Pennsylvania , majoring in a life sciences ... a two-year period. In addition, the selected Clarkston Scholar ... mentoring with Clarkston Consulting and participation in Pennsylvania Bio ...
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... , Oct. 8, 2015 The 2015 Nobel ... The University of Texas at Dallas. Aziz Sancar , ... Dallas in 1977, is one of three ... cells continuously monitor and repair damaged DNA on a molecular level.  ... molecular and cell biology from UT Dallas ...
(Date:10/8/2015)... , Oct. 8, 2015  The ALS Association, ... ALS Assistive Technology Challenge to revolutionize communication technology solutions ... --> ALS (amyotrophic lateral sclerosis) is ... in the brain and the spinal cord. Eventually, people ... muscle movement, which often leads to total paralysis and ...
Breaking Biology Technology:
... AARUHS, Denmark, July 6 ... the EmbryoScope(TM) Embryo,Monitoring System and EmbryoSlide(TM) tray have ... use in IVF. Unisense Fertilitech A/S also received,the ... installation and servicing of IVF incubators and related,accessories. ...
... Mass., July 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: ... amend the $29.5 million of outstanding 8% Senior Convertible Notes ... on July 1, 2009 is effective as of 8:00 a.m. ... Agreements with holders of 87% of the Notes, which is ...
... , REYKJAVIK, Iceland, July 6 Scientists at deCODE genetics ... and the United States today present in the journal ... for basal cell carcinoma (BCC) that affect people with fair ... single-letter variants in the sequence of the human genome (SNPs) ...
Cached Biology Technology:
(Date:10/7/2015)... , October 7, 2015 NXTD ... focused on the growing mobile commerce market and creator ... E. Washington , former long- term executive at American ... --> NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet ...
(Date:10/5/2015)... October 5, 2015 ... for NXT-ID, Inc. (NASDAQ: NXTD ), a biometric ... --> ) releases the ... NXTD ), a biometric authentication company focused on ... Technology Group ( ) releases the ...
(Date:9/30/2015)... Sept. 30, 2015  With nearly 300,000 Americans living ... new SCIs estimated to reach 12,500 annually, the role ... Resource Services for Independent Living (SCRS-IL) is increasingly ... California opening doors to independence for ... and services, notably assistive technology services and education. ...
Breaking Biology News(10 mins):
... researchers have demonstrated a new and more effective method ... a research advancement that could have major implications ... of death in the Western world. The treatment ... Aaron Baker could allow doctors to bypass surgery and ...
... In a worst-case scenario simulation of a foot-and-mouth disease ... surveillance system and raising a more resilient breed of ... industry should an outbreak of foot-and-mouth disease (FMD) or ... very quickly, such as foot-and-mouth, the best way to ...
... This press release is available in ... biochemical interest given the importance and diversity of the functions ... and serve as fuel for a number of biological systems; ... and, moreover, play a key role in cell processes. Recently ...
Cached Biology News:
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... 5 ml CELLection Dynabeads (4.5 m) coated ... epithelial antigen EpCAM and DNase Releasing Buffer. ... of epithelial tumour cells directly from blood, ... can be enriched from bone marrow. Enriched ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: